Program

Optimal use of the ToolboX for HCC treatment

Welcome and introduction, Pia Österlund(FI/S)

Case 1: Transplantation or ablation. Or: Too early to consider transplantation? Per Stål (S)

Case 2: Downstaging to transplantation. Or: Too advanced to consider transplantation?

Aki Uutela (FI)

Immunotherapy in the setting of liver transplantation – mission (im)possible?

Ghassan Abou-Alfa (US)

Discussion moderated by Pia Österlund

Thank you and goodbye, Pia Österlund

Learning goals:

·   Understanding of the management of HCC patients on the fringe of transplant eligibility.

·   Be aware of the challenges with immunotherapy in the liver transplant setting.

NOLCA

is pleased to present A new webinar ON

April 28, 2025 at 16:00-17:00 CET 

you can register for the webinar here:

                                                                                                                                       This webinar is supported by:

Eisai and AstraZeneca have had no influence on content of the agenda, nor speakers. The content is the property of the speakers. NOLCA and speakers are fully responsible for the medical and scientific content of the webinar.